Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Request a FREE Sample of our FcRn Binding Kit!
Request a FREE Sample of our Fc gamma RI / CD64 Binding Kit !
Happy Holiday! Limited Keychain here with your next orderHappy Holiday! Limited Keychain here with your next order
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
| Project Name | Modality | Therapeutic Area | Indications | Stage | Right Available |
| Reversible MAOB Inhibitor | Small molecule | Neurological disease | Parkinson's disease | Phase I | Global |
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| MAB-H5547 | Human | Human MAOB / Monoamine Oxidase B Protein, His Tag (active enzyme) |  |
|
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Rasagiline Mesylate | Lu 00-773; TVP-101; TV-1030; AGN-1135; TVP-1012 | Approved | Teva | Azilect, Agilect | EU | Parkinson Disease | Teva Bv | 2005-02-21 | Supranuclear Palsy, Progressive; Restless Legs Syndrome; Parkinson Disease; Dementia; Alzheimer Disease; Synucleinopathies; Multiple System Atrophy; REM Sleep Behavior Disorder | Details |
| Selegiline | Approved | Mylan Nv, Somerset Inc | Emsam | United States | Depressive Disorder, Major | Somerset Pharmaceuticals Inc | 2006-02-27 | Tobacco Use Cessation; Depressive Disorder, Major; Tobacco Use Disorder; Amphetamine-Related Disorders; Cocaine-Related Disorders | Details | |
| Selegiline Hydrochloride | FPF-1100; E-250 (free base) | Approved | Sanofi | FP, Jumex, Otrasel, Seledat, Xilopar, Zelapar, Deprenyl, Eldepryl, Plurimen, Vivapryl, Zydis selegiline | Mainland China | Parkinson Disease | Chinoin Pharmaceutical And Chemical Works Co Ltd | 1989-06-05 | HIV Infections; Marijuana Abuse; Parkinson Disease; Cognition Disorders | Details |
| Safinamide Methanesulfonate | PNU-151774; FCE-26743; PNU-151774E; FCE-28073 (R-isomer); EMD-1195686; ZP-034; NW-1015; ME-2125 | Approved | Newron Pharmaceutical | Xadago, Equfina | EU | Parkinson Disease | Zambon Spa | 2015-02-23 | Kidney Diseases; Parkinson Disease; Hepatic Insufficiency; Dyskinesia, Drug-Induced; Multiple System Atrophy | Details |
| Rasagiline Mesylate | Lu 00-773; TVP-101; TV-1030; AGN-1135; TVP-1012 | Approved | Teva | Azilect, Agilect | EU | Parkinson Disease | Teva Bv | 2005-02-21 | Supranuclear Palsy, Progressive; Restless Legs Syndrome; Parkinson Disease; Dementia; Alzheimer Disease; Synucleinopathies; Multiple System Atrophy; REM Sleep Behavior Disorder | Details |
| Selegiline | Approved | Mylan Nv, Somerset Inc | Emsam | United States | Depressive Disorder, Major | Somerset Pharmaceuticals Inc | 2006-02-27 | Tobacco Use Cessation; Depressive Disorder, Major; Tobacco Use Disorder; Amphetamine-Related Disorders; Cocaine-Related Disorders | Details | |
| Selegiline Hydrochloride | FPF-1100; E-250 (free base) | Approved | Sanofi | FP, Jumex, Otrasel, Seledat, Xilopar, Zelapar, Deprenyl, Eldepryl, Plurimen, Vivapryl, Zydis selegiline | Mainland China | Parkinson Disease | Chinoin Pharmaceutical And Chemical Works Co Ltd | 1989-06-05 | HIV Infections; Marijuana Abuse; Parkinson Disease; Cognition Disorders | Details |
| Safinamide Methanesulfonate | PNU-151774; FCE-26743; PNU-151774E; FCE-28073 (R-isomer); EMD-1195686; ZP-034; NW-1015; ME-2125 | Approved | Newron Pharmaceutical | Xadago, Equfina | EU | Parkinson Disease | Zambon Spa | 2015-02-23 | Kidney Diseases; Parkinson Disease; Hepatic Insufficiency; Dyskinesia, Drug-Induced; Multiple System Atrophy | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Pramipexole Dihydrochloride Hydrate/Rasagiline Mesylate | P2B-001 | Phase 3 Clinical | Pharma Two B Ltd | Parkinson Disease | Details |
| Vafidemstat | ORY-2001 | Phase 2 Clinical | Oryzon Genomics Sa | Schizophrenia; Alzheimer Disease; Kabuki syndrome; Borderline Personality Disorder | Details |
| Rasagiline transdermal patch (Teikoku Pharma) | Phase 1 Clinical | Teikoku Pharma | Parkinson Disease | Details | |
| J-147 | J-147 | Phase 1 Clinical | Salk Institute | Alzheimer Disease | Details |
| SKL-PD | YKP-10461; SKL-PD | Phase 1 Clinical | SK Biopharmaceuticals Co Ltd | Parkinson Disease | Details |
| PXS-5131 | PXS-5131 | Innovent Biologics(Suzhou) Co Ltd | Details | ||
| Pramipexole Dihydrochloride Hydrate/Rasagiline Mesylate | P2B-001 | Phase 3 Clinical | Pharma Two B Ltd | Parkinson Disease | Details |
| Vafidemstat | ORY-2001 | Phase 2 Clinical | Oryzon Genomics Sa | Schizophrenia; Alzheimer Disease; Kabuki syndrome; Borderline Personality Disorder | Details |
| Rasagiline transdermal patch (Teikoku Pharma) | Phase 1 Clinical | Teikoku Pharma | Parkinson Disease | Details | |
| J-147 | J-147 | Phase 1 Clinical | Salk Institute | Alzheimer Disease | Details |
| SKL-PD | YKP-10461; SKL-PD | Phase 1 Clinical | SK Biopharmaceuticals Co Ltd | Parkinson Disease | Details |
| PXS-5131 | PXS-5131 | Innovent Biologics(Suzhou) Co Ltd | Details |
This web search service is supported by Google Inc.
A-Z
